Pipeline ++ Our Pipeline
Modalities
Programs (Targets)
Discovery
Lead Optimization
IND Enabling Studies
Phase 1
Phase 2
Phase 3
Molecular Glues
BTX-1188 (GSPT1 + IKZF1/3)
Acute Myeloid Leukemia, Solid Tumors
Undisclosed glue discovery
Various
Bifunctional Degraders
SOS1
pan-KRAS Mutant Cancers
CDK4/6
Solid Tumors
CDK2/4/6
Solid Tumors
PDE4
Inflammatory Diseases
Programs (Targets): BTX-1188 (GSPT1 + IKZF1/3)
Modalities: Molecular Glues
Acute Myeloid Leukemia, Solid Tumors
Phase 1
Programs (Targets): Undisclosed glue discovery
Modalities: Molecular Glues
Various
Discovery
Programs (Targets): SOS1
Modalities: Bifunctional Degraders
pan-KRAS Mutant Cancers
Lead Optimization
Programs (Targets): CDK4/6
Modalities: Bifunctional Degraders
Solid Tumors
Lead Optimization
Programs (Targets): CDK2/4/6
Modalities: Bifunctional Degraders
Solid Tumors
Lead Optimization
Programs (Targets): PDE4
Modalities: Bifunctional Degraders
Inflammatory Diseases
Lead Optimization
*Full pipeline is wholly owned by Biotheryx.

Pipeline ++ Partner With Us
We are open to collaboration opportunities that fit with our mission and pipeline. Contact us at [email protected].